Federal judge dismisses kickback claims in Novartis whistleblower case — again
When a federal judge dismissed a whistleblower case against Novartis back in 2020, the court gave plaintiffs one last chance to prove the pharma giant bribed physicians to prescribe its multiple sclerosis drug Gilenya. On Tuesday, those efforts came up short.
US District Judge Kimba Wood of Southern New York ruled once again that former Novartis sales rep Steven Camburn’s complaint lacked sufficient detail to support claims that Novartis deployed a kickback scheme to boost Gilenya prescriptions.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.